312 related articles for article (PubMed ID: 25963435)
1. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
2. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
3. The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
Cerna T; Hrabeta J; Eckschlager T; Frei E; Schmeiser HH; Arlt VM; Stiborová M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29304031
[TBL] [Abstract][Full Text] [Related]
4. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
5. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
8. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid in the complex therapy of malignant tumors.
Hrebackova J; Hrabeta J; Eckschlager T
Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
11. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
12. Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Gavrilov V; Lavrenkov K; Ariad S; Shany S
Anticancer Res; 2014 Nov; 34(11):6565-72. PubMed ID: 25368259
[TBL] [Abstract][Full Text] [Related]
13. Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma.
Khalil MA; Hraběta J; Groh T; Procházka P; Doktorová H; Eckschlager T
PLoS One; 2016; 11(9):e0162916. PubMed ID: 27627801
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.
Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q
Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973
[TBL] [Abstract][Full Text] [Related]
15. Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Hajji N; Wallenborg K; Vlachos P; Füllgrabe J; Hermanson O; Joseph B
Oncogene; 2010 Apr; 29(15):2192-204. PubMed ID: 20118981
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Ozaki K; Kishikawa F; Tanaka M; Sakamoto T; Tanimura S; Kohno M
Cancer Sci; 2008 Feb; 99(2):376-84. PubMed ID: 18201278
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect of VPA on multiple myeloma U266 cell proliferation and regulation of histone acetylation].
Zhu YF; Ye BG; Shen JZ; Lin CM; Lin FA; Shen SF; Xu CB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):638-41. PubMed ID: 20561418
[TBL] [Abstract][Full Text] [Related]
19. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid overcomes hypoxia-induced resistance to apoptosis.
Cipro Š; Hřebačková J; Hraběta J; Poljaková J; Eckschlager T
Oncol Rep; 2012 Apr; 27(4):1219-26. PubMed ID: 22159638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
